



ADVANSOURCE BIOMATERIALS TO BE DELISTED FROM NYSE AMEX AND INTENDS TO TRADE ON OTCBB

Wilmington, MA. November 15, 2010... AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer, manufacturer and seller of advanced polymer technologies and materials for a broad range of medical devices, today announced it was notified by the NYSE Amex of its intent to delist the Company's common stock if an appeal is not submitted by November 16, 2010. Rather than appeal, the Company intends to qualify its common stock for trading on the Over-the-Counter Bulletin Board.

Michael Adams, AdvanSource's President and Chief Executive Officer, stated, "We believe our main focus should be on the continued execution of our business plan with the objective of continuing to grow our revenues and achieve profitability. To that end, we believe it is in the best interest of the Company and its shareholders to forego an appeal of the NYSE Amex's decision and begin the process of listing the Company's common stock on the Over The Counter Bulletin Board. We will keep our shareholders apprised of the details as we make this transition."

As previously announced, on August 17, 2010, the Company received a notice that it was not in compliance with one of the NYSE Amex's continued listing standards, specifically, Section 1003(a)(iii) of the NYSE Amex Company Guide because it reported stockholders' equity of less than \$6,000,000 and losses from continuing operations and net losses in its five most recent fiscal years.

About AdvanSource Biomaterials Corporation

AdvanSource Biomaterials Corporation manufactures advanced polymer materials which provide critical characteristics in the design and development of medical devices. The Company's biomaterials are used in devices that are designed for treating a broad range of anatomical sites and disease states. The Company's business model leverages its proprietary materials science technology and manufacturing expertise in order to expand its product sales and royalty and license fee income. More information about the Company is available at its website: www.advbiomaterials.com

Forward-Looking Statements

AdvanSource Biomaterials Corporation believes that this press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could cause results to differ materially from the forward-looking statements. For further information on such risks and uncertainties, you are encouraged to review the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended March 31, 2010 and its Quarterly Report on Form 10-Q for the quarters ended June 30, 2010 and September 30, 2010. The Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.

For further information contact:



AdvanSource Biomaterials Corporation

David Volpe, Acting CFO
(978) 657-0075, ext. 103
dvolpe@advbiomaterials.com